First-ever US clinical trial of engineered iPSC-derived cell therapy for blood cancer

A new cancer clinical trial has opened at the M Health Fairview University of Minnesota Medical Center that leverages the groundbreaking research on stem cells and natural killer (NK) cells done at the Masonic Cancer Center and applies it to attack acute myeloid leukemia (AML) and B-cell lymphoma. The first-of-its-kind NK cell cancer immunotherapy, called FT516, is manufactured from a […]

Read more